Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.

摘要: BACKGROUND Anemia is a common problem in the cancer population that result of clinical consequences. It also has adverse effects on patients' perceived quality life. Good management anemia therefore essential. A recent published trial demonstrated statistically significant increases hemoglobin levels and significantly increased QOL assessment following administration recombinant erythropoietin. OBJECTIVE To evaluate effectiveness, safety, life by using once weekly dosing Epoetin alfa (Eprex, Janssen-cilag) 40,000 units treatment patients receiving chemotherapy. SETTING Division Medical Oncology, Department Medicine, Faculty Chulalongkorn University Bangkok, Thailand. MATERIAL AND METHOD This was an open label, non-randomized study, 41 adult male female anemic who had non-myeloid malignancies upper area body part ranging from 9-11 g/dL chemotherapy at least 8 weeks with or without concurrent radiotherapy. The subjects were treated week subcutaneously. If, did not increase > 1.0 g/dl after 4 treatment, dose then to 60,000 per subcutaneously 5. would continue for total 16 weeks. Clinical outcome evaluated based linear analog scale (LASA) functional therapy-anemia (CU-QOL) instrument. Analyses performed determine incremental change associated increases. RESULTS Seventy six percent showed good response = 1 (Hb level before 9.82 +/- 0.78 12.56 1.49 g/dL, respectively; p < 0. 001). Improvement all primary cancer- anemia-specific domains, including energy ability do daily activities LASA fatigue assessed CU-QOL, greater (p 0.01) (233.94 56.01 18.45 13.07) compared baseline (202.58 36.74 25.09 11.00). well tolerated patients. CONCLUSION Once therapy safe effective remodeling improves Therefore, physician should maintain concentration normal improve their through period.